Lexeo Therapeutics, Inc.2024财年第三财季实现净利润-29.49百万美元，同比减少46.64%

市场透视11-23

11月23日，Lexeo Therapeutics, Inc.（LXEO.US）公布财报，公告显示公司2024财年第三财季净利润为-29.49百万美元，同比减少46.64%；其中营业收入为0.00美元，每股基本收益为-0.89美元。从资产负债表来看，Lexeo Therapeutics, Inc.（LXEO.US）总负债34.54百万美元，其中短期债务2.68百万美元，资产负债比为0.06，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485937042?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485937042","market":"us","top_or_hot":-1,"title":"Lexeo Therapeutics, Inc.2024财年第三财季实现净利润-29.49百万美元，同比减少46.64%","media":"市场透视","content":"<div>\n<p>11月23日，Lexeo Therapeutics, Inc.（LXEO.US）公布财报，公告显示公司2024财年第三财季净利润为-29.49百万美元，同比减少46.64%；其中营业收入为0.00美元，每股基本收益为-0.89美元。从资产负债表来看，Lexeo Therapeutics, Inc.（LXEO.US）总负债34.54百万美元，其中短期债务2.68百万美元，资产负债比为0.06，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000038a24e482c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo Therapeutics, Inc.2024财年第三财季实现净利润-29.49百万美元，同比减少46.64%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo Therapeutics, Inc.2024财年第三财季实现净利润-29.49百万美元，同比减少46.64%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000038a24e482c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Lexeo Therapeutics, Inc.（LXEO.US）公布财报，公告显示公司2024财年第三财季净利润为-29.49百万美元，同比减少46.64%；其中营业收入为0.00美元，每股基本收益为-0.89美元。从资产负债表来看，Lexeo Therapeutics, Inc.（LXEO.US）总负债34.54百万美元，其中短期债务2.68百万美元，资产负债比为0.06，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000038a24e482c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXEO","symbol_name":"Lexeo Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000038a24e482c&s=b","article_id":"2485937042","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000038a24e482c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485937042","pubTimestamp":1732291220,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Lexeo Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-29.49百万美元，同比减少46.64%；其中营业收入为0.00美元，每股基本收益为-0.89美元。从资产负债表来看，Lexeo Therapeutics, Inc.总负债34.54百万美元，其中短期债务2.68百万美元，资产负债比为0.06，流动比率为0.06。机构评级：截至2024年11月23日，当前有7家机构对Lexeo Therapeutics, Inc.目标价做出预测，其中目标均价为22.29美元，其中最低目标价为16.00美元，最高目标价为28.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LXEO":"Lexeo Therapeutics","LENZ":"Therapeutics"},"translate_title":"Lexeo Therapeutics, Inc. achieved net profit of-29.49 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 46.64%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"LXEO":1},"content_text":"11月23日，Lexeo Therapeutics, Inc.（LXEO.US）公布财报，公告显示公司2024财年第三财季净利润为-29.49百万美元，同比减少46.64%；其中营业收入为0.00美元，每股基本收益为-0.89美元。从资产负债表来看，Lexeo Therapeutics, Inc.（LXEO.US）总负债34.54百万美元，其中短期债务2.68百万美元，资产负债比为0.06，流动比率为0.06。机构评级：截至2024年11月23日，当前有7家机构对Lexeo Therapeutics, Inc.目标价做出预测，其中目标均价为22.29美元，其中最低目标价为16.00美元，最高目标价为28.00美元。公司简介：Lexeo Therapeutics Inc 是一家临床阶段的基因药物公司，致力于通过应用前沿科学从根本上改变疾病的治疗方式来改变医疗保健。其产品线包括针对给社会带来重大负担且最适合其基因医学方法的患者群体的候选药物。该公司专注于临床前和临床阶段的基因治疗，特别是高未满足需求的遗传性和后天性疾病，这是他们唯一的业务分部。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485937042"}